Extension Study of Participants From SPG302-ALS-001

NCT06903286 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

16

Enrollment

INDUSTRY

Sponsor class

Stopped patients treated through compassionate use program

Conditions

Amyotrophic Lateral Sclerosis (ALS)

Interventions

DRUG: SPG302

Sponsor

Spinogenix